These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 26198591)

  • 1. Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease.
    Niccolini F; Haider S; Reis Marques T; Muhlert N; Tziortzi AC; Searle GE; Natesan S; Piccini P; Kapur S; Rabiner EA; Gunn RN; Tabrizi SJ; Politis M
    Brain; 2015 Oct; 138(Pt 10):3016-29. PubMed ID: 26198591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers.
    Wilson H; Niccolini F; Haider S; Marques TR; Pagano G; Coello C; Natesan S; Kapur S; Rabiner EA; Gunn RN; Tabrizi SJ; Politis M
    J Neurol Sci; 2016 Sep; 368():243-8. PubMed ID: 27538642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease.
    Niccolini F; Foltynie T; Reis Marques T; Muhlert N; Tziortzi AC; Searle GE; Natesan S; Kapur S; Rabiner EA; Gunn RN; Piccini P; Politis M
    Brain; 2015 Oct; 138(Pt 10):3003-15. PubMed ID: 26210536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET Molecular Imaging of Phosphodiesterase 10A: An Early Biomarker of Huntington's Disease Progression.
    Fazio P; Fitzer-Attas CJ; Mrzljak L; Bronzova J; Nag S; Warner JH; Landwehrmeyer B; Al-Tawil N; Halldin C; Forsberg A; Ware J; Dilda V; Wood A; Sampaio C; Varrone A;
    Mov Disord; 2020 Apr; 35(4):606-615. PubMed ID: 31967355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease.
    Giampà C; Laurenti D; Anzilotti S; Bernardi G; Menniti FS; Fusco FR
    PLoS One; 2010 Oct; 5(10):e13417. PubMed ID: 20976216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms.
    Hebb AL; Robertson HA; Denovan-Wright EM
    Neuroscience; 2004; 123(4):967-81. PubMed ID: 14751289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease.
    Kleiman RJ; Kimmel LH; Bove SE; Lanz TA; Harms JF; Romegialli A; Miller KS; Willis A; des Etages S; Kuhn M; Schmidt CJ
    J Pharmacol Exp Ther; 2011 Jan; 336(1):64-76. PubMed ID: 20923867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Imaging Markers to Track Huntington's Disease Pathology.
    Wilson H; De Micco R; Niccolini F; Politis M
    Front Neurol; 2017; 8():11. PubMed ID: 28194132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease.
    Russell DS; Barret O; Jennings DL; Friedman JH; Tamagnan GD; Thomae D; Alagille D; Morley TJ; Papin C; Papapetropoulos S; Waterhouse RN; Seibyl JP; Marek KL
    JAMA Neurol; 2014 Dec; 71(12):1520-8. PubMed ID: 25322077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease.
    Leuti A; Laurenti D; Giampà C; Montagna E; Dato C; Anzilotti S; Melone MA; Bernardi G; Fusco FR
    Neurobiol Dis; 2013 Apr; 52():104-16. PubMed ID: 23220622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice.
    Ooms M; Rietjens R; Rangarajan JR; Vunckx K; Valdeolivas S; Maes F; Himmelreich U; Fernandez-Ruiz J; Bormans G; Van Laere K; Casteels C
    Neurobiol Aging; 2014 Dec; 35(12):2858-2869. PubMed ID: 25018107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Striatal molecular alterations in HD gene carriers: a systematic review and meta-analysis of PET studies.
    Niccolini F; Pagano G; Fusar-Poli P; Wood A; Mrzljak L; Sampaio C; Politis M
    J Neurol Neurosurg Psychiatry; 2018 Feb; 89(2):185-196. PubMed ID: 28889093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase-10A Inverse Changes in Striatopallidal and Striatoentopeduncular Pathways of a Transgenic Mouse Model of
    D'Angelo V; Castelli V; Giorgi M; Cardarelli S; Saverioni I; Palumbo F; Bonsi P; Pisani A; Giampà C; Sorge R; Biagioni S; Fusco FR; Sancesario G
    J Neurosci; 2017 Feb; 37(8):2112-2124. PubMed ID: 28115486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Huntingtin silencing delays onset and slows progression of Huntington's disease: a biomarker study.
    Liu H; Zhang C; Xu J; Jin J; Cheng L; Miao X; Wu Q; Wei Z; Liu P; Lu H; van Zijl PCM; Ross CA; Hua J; Duan W
    Brain; 2021 Nov; 144(10):3101-3113. PubMed ID: 34043007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of phosphodiesterase 10A, dopamine receptors D1 and D2 and dopamine transporter ligand binding in the striatum of the R6/2 and BACHD mouse models of Huntington's disease.
    Miller S; Hill Della Puppa G; Reidling J; Marcora E; Thompson LM; Treanor J
    J Huntingtons Dis; 2014; 3(4):333-41. PubMed ID: 25575954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the binding properties of T-773 as a PET radioligand for phosphodiesterase 10A.
    Harada A; Suzuki K; Miura S; Hasui T; Kamiguchi N; Ishii T; Taniguchi T; Kuroita T; Takano A; Stepanov V; Halldin C; Kimura H
    Nucl Med Biol; 2015 Feb; 42(2):146-54. PubMed ID: 25451212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant huntingtin affects the rate of transcription of striatum-specific isoforms of phosphodiesterase 10A.
    Hu H; McCaw EA; Hebb AL; Gomez GT; Denovan-Wright EM
    Eur J Neurosci; 2004 Dec; 20(12):3351-63. PubMed ID: 15610167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAK-063, a Novel Phosphodiesterase 10A Inhibitor, Protects from Striatal Neurodegeneration and Ameliorates Behavioral Deficits in the R6/2 Mouse Model of Huntington's Disease.
    Harada A; Suzuki K; Kimura H
    J Pharmacol Exp Ther; 2017 Jan; 360(1):75-83. PubMed ID: 27811172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study.
    Politis M; Pavese N; Tai YF; Kiferle L; Mason SL; Brooks DJ; Tabrizi SJ; Barker RA; Piccini P
    Hum Brain Mapp; 2011 Feb; 32(2):258-70. PubMed ID: 21229614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PET imaging shows loss of striatal PDE10A in patients with Huntington disease.
    Ahmad R; Bourgeois S; Postnov A; Schmidt ME; Bormans G; Van Laere K; Vandenberghe W
    Neurology; 2014 Jan; 82(3):279-81. PubMed ID: 24353339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.